| Project/Area Number |
23390318
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKEUCHI Kaoru 筑波大学, 医学医療系, 准教授 (00192162)
YANAGAWA Toru 東京女子医科大学, 医学部, 講師 (00338980)
YANAGAWA Toru 筑波大学, 医学医療系, 准教授 (10312852)
YAMAMOTO Masakazu 東京女子医科大学, 医学部, 教授 (60220498)
KAWAKAMI Koji 京都大学, 医学系研究科, 教授 (70422318)
SHODA Junichi 筑波大学, 医学医療系, 教授 (90241827)
|
|---|
| Project Period (FY) |
2011-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥18,980,000 (Direct Cost: ¥14,600,000、Indirect Cost: ¥4,380,000)
Fiscal Year 2013: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2011: ¥9,490,000 (Direct Cost: ¥7,300,000、Indirect Cost: ¥2,190,000)
|
|---|
| Keywords | 胆道系悪性腫瘍 / 分子標的治療 / ハイブリッドペプチド / サイトカイン / 受容体 |
|---|
| Research Abstract |
It is known that the interleukin-4 receptor alpha (IL-4R alpha) is highly expressed on the surface of various human solid tumors. We have newly designed IL-4R alpha-lytic hybrid peptide composed of binding peptide to IL-4R alpha and cell-lytic peptide. Here, we evaluated the antitumor activity of the IL-4R alpha-lytic hybrid peptide as a novel molecular targeted therapy in human biliary tract cancer (BTC) cells. IL-4R alpha-lytic hybrid peptide showed cytotoxic activity in siz BTC cell lines with a concentration that killed 50% of all cells (IC50) as low as 5 micromoles/L. In addition, intravenous administration of IL-4R alpha-lytic hybrid peptide significantly inhibited tumor growth in a xenograft model of human BTC in vivo. Taken together, these results indicated that the IL-4R alpha-lytic hybrid peptide is a potent agent that might provide a novel therapy for patients with BTC.
|
